PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681354
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1681354
The global cystoscope market was valued at approximately USD 1.12 billion in 2023 and is projected to grow at a CAGR of 9.99% from 2024 to 2032. The increasing prevalence of urological and gynecological disorders, a growing geriatric population, and technological advancements in cystoscope devices are key factors driving the market.
Cystoscopes are widely used for the diagnosis and treatment of urinary tract disorders, bladder cancer, urinary incontinence, and urinary tract infections (UTIs). According to a 2024 study published by Elsevier Inc., 50%-60% of women experience at least one UTI in their lifetime, significantly increasing the demand for cystoscopic procedures. Additionally, a WHO report (2024) estimates that by 2030, around 16.66% of the global population will be aged 60 or older, contributing to a higher prevalence of urological conditions such as benign prostatic hyperplasia (BPH), bladder stones, and bladder cancer.
The rising incidence of bladder cancer is also a major growth driver for the cystoscope market. The International Agency for Research on Cancer (2022) reported that over 600,000 people worldwide were diagnosed with bladder cancer, leading to more than 220,000 deaths. Since cystoscopy is the primary diagnostic tool for bladder cancer, the increasing disease burden is expected to propel market demand over the forecast period.
Technological innovations are transforming cystoscopy procedures, improving patient comfort and diagnostic accuracy. For instance, UroViu Corp introduced the Uro-GHD in April 2023, a single-use, sterile cystoscope designed for enhanced flexibility and improved patient comfort. Additionally, Ambu Inc. received FDA approval for the aScope 4 Cysto in 2021, expanding the availability of video cystoscopy solutions. The adoption of single-use cystoscopes is rising due to infection control concerns, reducing the risk of cross-contamination and healthcare-associated infections (HAIs).
From a regional perspective, North America held the largest market share in 2023, driven by advanced healthcare infrastructure, increasing incidence of bladder cancer, and strong presence of key market players such as Olympus Corporation, Boston Scientific Corporation, and Ambu Inc.. Meanwhile, the Asia Pacific region is projected to witness the fastest growth, fueled by rising healthcare investments, increasing awareness of urological disorders, and expanding access to diagnostic facilities in countries such as China, India, and Japan.